Mirla Avila and Susan Payrovi, MDs, explain MS progression, relapse vs. change, and subtle signs that matter even with a ...
Swiss biotech Oculis is poised to start registration trials for privosegtor, its drug candidate for neuro-ophthalmic diseases, in the wake of encouraging phase 2 data. The Zug-based company said ...
A neurologist explains how Multiple Sclerosis begins, the early symptoms to watch out for, and current treatment options that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback